GenBank accession numbers for the sequences reported here are GU565657-GU565681.
Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug–resistant strains: 2005 through 2007
Article first published online: 23 JUN 2010
© 2010 American Association of Blood Banks
Volume 50, Issue 12, pages 2707–2712, December 2010
How to Cite
Brennan, C. A., Yamaguchi, J., Devare, S. G., Foster, G. A. and Stramer, S. L. (2010), Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug–resistant strains: 2005 through 2007. Transfusion, 50: 2707–2712. doi: 10.1111/j.1537-2995.2010.02767.x
- Issue published online: 3 DEC 2010
- Article first published online: 23 JUN 2010
- Received for publication April 9, 2010; revision received May 4, 2010, and accepted May 4, 2010.
BACKGROUND: In a previous study of 66 human immunodeficiency virus (HIV)-infected US blood donors from 1999 to 2005, HIV-1 non-B and antiretroviral drug–resistant strains accounted for 4.7 and 6.5% of HIV infections, respectively. This study was expanded to include an additional 11 recently acquired infections and 197 established infections collected from January 2005 through December 2007.
STUDY DESIGN AND METHODS: HIV-infected donors were detected using FDA-licensed assays. Drug resistance profiles for protease and reverse transcriptase (RT) genes were determined using a genotyping system (ViroSeq, Celera Diagnostics); genetic subtype was determined by phylogenetic analysis of these sequences.
RESULTS: Drug resistance profiles were obtained for 203 of 208 specimens; 9.9% had mutations that confer drug resistance. Ten showed resistance to a single drug class: nine to nonnucleoside RT inhibitors (NNRTIs) and one to nucleoside RT inhibitors (NRTIs). Eight showed two drug class resistance: five NRTI plus NNRTI, two NRTI plus protease inhibitor (PI), and one NNRTI plus PI. Two showed three drug class resistance. Non-B strains were identified in 2.5% of donors and consisted of subtypes A1 and D, CRF02_AG, CRF43-02G, and URF_BF.
CONCLUSIONS: Data from this and the previous study show that antiretroviral drug–resistant HIV-1 is present in 9.1% of HIV-infected donors from 1999 through 2007; 9.3% of established infections and 6.9% of recent infections. Diverse HIV-1 non-B strains presently account for 3.0% of HIV infections in US donors.